颖泰生物(833819) - 2024 Q4 - 年度业绩

Financial Performance - The company's operating revenue for 2024 is expected to be ¥5,832,265,391.65, a decrease of 0.61% compared to the previous year[4] - The total profit for the period is projected to be -¥577,528,392.91, representing a decline of 453.84% year-over-year[4] - The net profit attributable to shareholders is expected to be -¥551,134,452.59, a decrease of 676.00% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses is projected to be -¥549,194,034.88, down 1,216.26% year-over-year[4] - The basic earnings per share is expected to be -¥0.45, a decline of 662.50% compared to the previous year[4] Assets and Equity - Total assets at the end of the reporting period are expected to be ¥11,947,971,106.93, a decrease of 5.49% from the beginning of the period[5] - Shareholders' equity is projected to be ¥5,069,345,743.79, down 12.37% from the beginning of the period[5] - The estimated net asset value per share attributable to shareholders is expected to be ¥4.14, a decrease of 12.29% from the beginning of the period[5] Market Conditions - The decline in performance is attributed to factors such as slowing customer demand and intensified market competition, leading to lower product prices and gross margins[6][7] - The company has recognized impairment provisions for certain asset groups due to ongoing price declines, significantly impacting net profit[7]